Distinguished in Embryonal Tumor with Multilayered Rosettes

Karsten Nysom

Copenhagen, DK 
Clinical Trials:Currently Recruiting for 1 Trial
Distinguished in Embryonal Tumor with Multilayered Rosettes
Copenhagen, DK 
OverviewLocationsClinical Research

Overview

Karsten Nysom practices in Copenhagen, Denmark. Mr. Nysom is rated as a Distinguished expert by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. His top areas of expertise are Embryonal Tumor with Multilayered Rosettes, Neuroblastoma, Gliomatosis Cerebri, and Selective Mutism.

His clinical research consists of co-authoring 68 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 9 articles and participated in 3 clinical trials in the study of Embryonal Tumor with Multilayered Rosettes.

Gender
Male

Locations

Copenhagen, Denmark
Other Locations
Denmark

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase II Study of Metronomic and Targeted Anti-angiogenesis Therapy for Children with Recurrent/progressive Medulloblastoma, Ependymoma and ATRT
A Phase II Study of Metronomic and Targeted Anti-angiogenesis Therapy for Children with Recurrent/progressive Medulloblastoma, Ependymoma and ATRT
Enrollment Status: Recruiting
Publish Date: October 21, 2024
Intervention Type: Drug
Study Drugs: Bevacizumab, Thalidomide, Celecoxib, Fenofibric Acid, Etoposide, Cyclophosphamide, Etoposide Phosphate, Cytarabine
Study Phase: Phase 2
A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
Enrollment Status: Completed
Publish Date: October 03, 2024
Intervention Type: Drug
Study Drug: Tazemetostat
Study Phase: Phase 1
A Randomised Phase IIb Trial of Bevacizumab Added to Temozolomide ± Irinotecan for Children With Refractory/Relapsed Neuroblastoma - BEACON-Neuroblastoma Trial
A Randomised Phase IIb Trial of Bevacizumab Added to Temozolomide ± Irinotecan for Children With Refractory/Relapsed Neuroblastoma - BEACON-Neuroblastoma Trial
Enrollment Status: Active_not_recruiting
Publish Date: May 14, 2024
Intervention Type: Drug
Study Drugs: Bevacizumab, Temozolomide, Irinotecan, Topotecan, Dinutuximab Beta, Cyclophosphamide
Study Phase: Phase 2
A Multicenter Phase 2/3 Trial of the Efficacy and Safety of Intracerebroventricular Radioimmunotherapy Using 131I-omburtamab for Neuroblastoma Central Nervous System/Leptomeningeal Metastases
A Multicenter Phase 2/3 Trial of the Efficacy and Safety of Intracerebroventricular Radioimmunotherapy Using 131I-omburtamab for Neuroblastoma Central Nervous System/Leptomeningeal Metastases
Enrollment Status: Terminated
Publish Date: February 13, 2024
Intervention Type: Biological
Study Drug: 131I-omburtamab
Study Phase: Phase 2/Phase 3
Phase I-II Study of Vinblastine in Combination With Nilotinib in Children, Adolescents, and Young Adults With Refractory or Recurrent Low-Grade Glioma
Phase I-II Study of Vinblastine in Combination With Nilotinib in Children, Adolescents, and Young Adults With Refractory or Recurrent Low-Grade Glioma
Enrollment Status: Terminated
Publish Date: May 31, 2022
Intervention Type: Drug
Study Drugs: Vinblastine+Nilotinib, Vinblastine
Study Phase: Phase 2
PHASE I-II STUDY OF VINBLASTINE IN COMBINATION WITH NILOTINIB IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH REFRACTORY OR RECURRENT LOW-GRADE GLIOMA
PHASE I-II STUDY OF VINBLASTINE IN COMBINATION WITH NILOTINIB IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH REFRACTORY OR RECURRENT LOW-GRADE GLIOMA
Enrollment Status: Completed
Publish Date: May 27, 2022
Intervention Type: Drug
Study Drugs: Nilotinib, Vinblastine
Study Phase: Phase 1
View 5 Less Clinical Trials

68 Total Publications

Assessment of peripheral blood DNA methylation signatures as pharmacodynamic and predictive biomarkers during azacitidine therapy in juvenile myelomonocytic leukaemia: Results of the EWOG-MESRAT study.
Assessment of peripheral blood DNA methylation signatures as pharmacodynamic and predictive biomarkers during azacitidine therapy in juvenile myelomonocytic leukaemia: Results of the EWOG-MESRAT study.
Journal: British journal of haematology
Published: May 27, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Nysom's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 21 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile